GlassScriptPhysician profile
Paul Andrew Kyser
NPI 1124339437
$2,693.64
in general payments reported to CMS, 2019-2025
24 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2022: $419 · 2023: $858 · 2024: $660 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $644.60 | 2022-2025 | Azstarys |
| Pfizer INC. | $514.28 | 2022-2025 | |
| Lilly USA, LLC | $358.87 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $218.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $149.67 | 2022-2025 | |
| Genentech USA, INC. | $124.35 | 2019 | |
| Supernus Pharmaceuticals, INC. | $101.60 | 2022-2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $83.31 | 2022-2023 | Jornay Pm |
| Scilex Pharmaceuticals INC. | $60.89 | 2024 | |
| Glaxosmithkline, LLC. | $54.01 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $52.39 | 2024-2025 | Voquezna |
| Abbvie INC. | $49.98 | 2022 | |
| Acadia Pharmaceuticals INC | $49.04 | 2025 | Daybue |
| Novo Nordisk INC | $47.34 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Sanofi Pasteur INC. | $31.22 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $30.31 | 2023 | Freestyle Libre 2 |
| Tris Pharma INC | $20.36 | 2025 | Dyanavel Xr |
| Astrazeneca Pharmaceuticals LP | $18.18 | 2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $17.44 | 2025 | |
| Amgen INC. | $15.01 | 2024 | Repatha |
| Nevro Corp. | $13.37 | 2022 | |
| Inspire Medical Systems, INC. | $13.09 | 2024 | Inspire |
| Dynavax Technologies Corporation | $13.05 | 2025 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kyser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.